Qualigen Therapeutics Inc. Revenue 2020–2022
Qualigen Therapeutics Inc. annual/quarterly revenue history and growth rate from 2020 to 2023. Revenue can be defined as the amount of money a company receives from its customers in exchange for the sale of goods or services. Revenue is the top line item on an income statement from which all costs and expenses are subtracted to arrive at net income.
- Qualigen Therapeutics Inc. revenue for the quarter ending June 30, 2023 was 1.6 M, a 13.74% increase year-over-year.
- Qualigen Therapeutics Inc. revenue for the twelve months ending June 30, 2023 was 6.1 M, a 24.75% increase year-over-year.
- Qualigen Therapeutics Inc. annual revenue for 2022 was 5.0 M, a 11.85% decrease from 2021.
- Qualigen Therapeutics Inc. annual revenue for 2021 was 5.7 M, a 31.29% increase from 2020.
- Qualigen Therapeutics Inc. annual revenue for 2020 was 4.3 M, a 22.52% decrease from 2020.
- Qualigen Therapeutics Inc. annual revenue for 2020 was 5.6 M.
Qualigen Therapeutics Inc. (AIXC) — Frequently Asked Questions
Qualigen Therapeutics Inc. (AIXC) is a publicly traded US company. It has a market capitalization of $5M. In fiscal 2022 it reported revenue of $5M and net income of -$19M. Explore AIXC's stock price, financial statements, earnings history, margins and key ratios below.
What is Qualigen Therapeutics Inc.'s market cap?
Qualigen Therapeutics Inc. (AIXC) has a market capitalization of $5M.
What is the AIXC stock price?
AIXC trades at $1.29 (+0.78% on the day).
How much revenue does Qualigen Therapeutics Inc. make?
Qualigen Therapeutics Inc. reported revenue of $5M in fiscal 2022.
Is AIXC profitable?
In fiscal 2022, Qualigen Therapeutics Inc. reported net income of -$19M.